Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Myeloid

ClinicalTrials.gov lists 4,637 trials for Leukemia, Myeloid or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 192.

MeSH D007951 Neoplasms Neoplasm C04 C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,209 Phase 1/2 Phase 1/2 585 Phase 2 Phase 2 1,369 Phase 2/3 Phase 2/3 76 Phase 3 Phase 3 379 Phase 4 Phase 4 83 Not applicable Not applicable 328 Observational Observational 577 Phase 1 Phase 1 1,209 Phase 1/2 Phase 1/2 585 Phase 2 Phase 2 1,369 Phase 2/3 Phase 2/3 76 Phase 3 Phase 3 379 Phase 4 Phase 4 83 Not applicable Not applicable 328 Observational Observational 577

Trials per phase

2 more sections with rows

135 of the 4,637 trials are tagged with Leukemia, Myeloid itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Myeloid report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Myeloid trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 233

1990: 1 trials (Phase 2 1) 1991: 3 trials (Observational 1, Phase 2 1, Phase 1 1) 1992: 4 trials (Not applicable 1, Phase 2 2, Phase 1 1) 1993: 9 trials (Not applicable 1, Phase 3 4, Phase 2 4) 1994: 9 trials (Phase 3 1, Phase 2 7, Phase 1 1) 1995: 21 trials (Observational 2, Not applicable 1, Phase 3 6, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 3) 1996: 23 trials (Observational 2, Phase 4 1, Phase 3 7, Phase 2 7, Phase 1/2 2, Phase 1 4) 1997: 29 trials (Not applicable 2, Phase 3 5, Phase 2 12, Phase 1/2 3, Phase 1 7) 1998: 55 trials (Observational 2, Not applicable 2, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 23, Phase 1/2 5, Phase 1 11) 1999: 76 trials (Observational 4, Not applicable 4, Phase 4 1, Phase 3 11, Phase 2/3 2, Phase 2 27, Phase 1/2 7, Phase 1 20) 2000: 78 trials (Observational 3, Not applicable 5, Phase 4 2, Phase 3 11, Phase 2/3 1, Phase 2 34, Phase 1/2 8, Phase 1 14) 2001: 75 trials (Observational 4, Not applicable 7, Phase 3 3, Phase 2/3 2, Phase 2 37, Phase 1/2 12, Phase 1 10) 2002: 81 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 3 15, Phase 2/3 1, Phase 2 29, Phase 1/2 8, Phase 1 18) 2003: 81 trials (Observational 7, Not applicable 8, Phase 4 4, Phase 3 6, Phase 2 34, Phase 1/2 8, Phase 1 14) 2004: 118 trials (Observational 8, Not applicable 9, Phase 4 1, Phase 3 14, Phase 2/3 5, Phase 2 42, Phase 1/2 14, Phase 1 25) 2005: 131 trials (Observational 6, Not applicable 7, Phase 4 5, Phase 3 12, Phase 2/3 1, Phase 2 48, Phase 1/2 18, Phase 1 34) 2006: 138 trials (Other 2, Observational 11, Not applicable 9, Phase 4 1, Phase 3 13, Phase 2/3 5, Phase 2 55, Phase 1/2 18, Phase 1 24) 2007: 153 trials (Other 1, Observational 15, Not applicable 11, Phase 4 4, Phase 3 16, Phase 2/3 1, Phase 2 52, Phase 1/2 17, Phase 1 36) 2008: 140 trials (Other 1, Observational 17, Not applicable 9, Phase 4 2, Phase 3 14, Phase 2/3 1, Phase 2 51, Phase 1/2 16, Phase 1 29) 2009: 146 trials (Other 1, Observational 17, Not applicable 9, Phase 4 4, Phase 3 11, Phase 2/3 4, Phase 2 49, Phase 1/2 16, Phase 1 35) 2010: 165 trials (Observational 32, Not applicable 9, Phase 4 8, Phase 3 14, Phase 2 45, Phase 1/2 13, Phase 1 44) 2011: 156 trials (Observational 26, Not applicable 4, Phase 4 2, Phase 3 14, Phase 2 58, Phase 1/2 17, Phase 1 35) 2012: 147 trials (Observational 16, Not applicable 5, Phase 4 2, Phase 3 13, Phase 2/3 1, Phase 2 47, Phase 1/2 20, Phase 1 43) 2013: 172 trials (Observational 20, Not applicable 10, Phase 4 8, Phase 3 6, Phase 2/3 3, Phase 2 64, Phase 1/2 28, Phase 1 33) 2014: 164 trials (Observational 26, Not applicable 7, Phase 4 3, Phase 3 17, Phase 2/3 2, Phase 2 36, Phase 1/2 24, Phase 1 49) 2015: 172 trials (Observational 15, Not applicable 15, Phase 4 3, Phase 3 10, Phase 2/3 5, Phase 2 54, Phase 1/2 25, Phase 1 45) 2016: 184 trials (Observational 21, Not applicable 9, Phase 4 6, Phase 3 13, Phase 2/3 2, Phase 2 48, Phase 1/2 28, Phase 1 57) 2017: 185 trials (Observational 31, Not applicable 13, Phase 4 2, Phase 3 14, Phase 2/3 1, Phase 2 45, Phase 1/2 27, Phase 1 52) 2018: 197 trials (Observational 23, Not applicable 7, Phase 3 15, Phase 2/3 8, Phase 2 53, Phase 1/2 22, Phase 1 69) 2019: 202 trials (Observational 22, Not applicable 17, Phase 4 4, Phase 3 19, Phase 2/3 1, Phase 2 52, Phase 1/2 31, Phase 1 56) 2020: 198 trials (Observational 36, Not applicable 13, Phase 3 8, Phase 2/3 3, Phase 2 45, Phase 1/2 30, Phase 1 63) 2021: 213 trials (Observational 31, Not applicable 22, Phase 4 3, Phase 3 15, Phase 2/3 3, Phase 2 48, Phase 1/2 37, Phase 1 54) 2022: 213 trials (Observational 36, Not applicable 17, Phase 4 5, Phase 3 14, Phase 2/3 2, Phase 2 38, Phase 1/2 32, Phase 1 69) 2023: 189 trials (Observational 38, Not applicable 22, Phase 3 12, Phase 2/3 3, Phase 2 38, Phase 1/2 24, Phase 1 52) 2024: 233 trials (Observational 35, Not applicable 18, Phase 4 4, Phase 3 11, Phase 2/3 3, Phase 2 59, Phase 1/2 28, Phase 1 75) 2025: 198 trials (Observational 28, Not applicable 25, Phase 4 3, Phase 3 11, Phase 2/3 3, Phase 2 48, Phase 1/2 17, Phase 1 63)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 222
2025 198
2024 233
2023 189
2022 213
2021 213
2020 198
2019 202
2018 197
2017 185

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 560 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 2,869 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Myeloid trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,209
Phase 1/2 585
Phase 2 1,369
Phase 2/3 76
Phase 3 379
Phase 4 83
Not applicable 328
Observational 577
Expanded access 30
Unknown 1

How many Leukemia, Myeloid trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 174
Recruiting 633
Enrolling by invitation 21
Active, not recruiting 271
Available 8

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Myeloid trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 192
Novartis Pharmaceuticals 130
Children's Oncology Group 49
AbbVie 42
Bristol-Myers Squibb 42

Which drugs are being tested for Leukemia, Myeloid? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 327
Busulfan 205
Decitabine 175
Imatinib 147

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cytarabine IT 517
SQ Fludarabine 409
Azacitidine MTD 356
Venetoclax 600 295
Mofetil Mycophenolate 166

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Myeloid trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 6,050 351
Pneumonia 3,511 291
Sepsis 2,616 403
Anemia 2,604 78
Platelet count decreased 2,312 128

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Myeloid? (349)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. Leukemia research 2022 Yes
A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leukemia research 2022 Yes
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nature communications 2021 Yes
Treatment advances for pediatric and adult onset neoplasms with monocytosis. Current hematologic malignancy reports 2021 Yes
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. The New England journal of medicine 2019 Yes

Showing 5 of 349 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages